Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy

This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.

Nearly half of all clinical trials not published

Nearly half of all clinical trials not published

Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35

Latest news

More from news
Approximately 7 fully matching, plus 107 partially matching documents found.

Latest Intelligence

  • Pharma deals in April 2015 Pharma deals in April 2015

    The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy

  • Allergan and taking a specialised approach Allergan and taking a specialised approach

    But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and

  • Pharma deals during April 2014 Pharma deals during April 2014

    The total cost of the all-stock acquisition is $4.0bn (an 18% premium), $3.2bn in stock and nearly $800m of Ranbaxy debt. ... Eclipsing all else will be restoring FDA confidence. To this end immediate remedial action will involve management restructuring

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.

  • Positive prospects for pharma in Latin America Positive prospects for pharma in Latin America

    Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Competition from within

    Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘ BRIC’ markets (Brazil,

  • Exploring MINT: Part 3 - Nigeria

    At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.

  • Exploring MINT: Part 3 - Nigeria

    At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics